Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 3, and 4).”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Compared to the most common APOE3/3 genotype, which is considered neutral with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia onset, and each additional copy of APOE4 is associated with a higher risk and younger age at onset.10”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citation
Research works printed but not linked: 2
- Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
- Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
Cited by
Items 801–900 of 1,029
Isoform-specific effects of apoE on neurite outgrowth in olfactory epithelium culture
Hussain, A., Luong, M., Pooley, A., & Nathan, B. P. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-49 · Cited by 34
“Numerous genetic studies have revealed that inheritance of apoE4 allele increases the risk and rate of progression of late-onset Alzheimer disease [5-9].”
New Insights into the Molecular Bases of Familial Alzheimer’s Disease
D’Argenio, V., & Sarnataro, D. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020026 · Cited by 44
“Interestingly, the ε2 allele has been reported as a protective factor, reducing the AD risk and also positively impacting longevity [52].”
BackgroundTucker, A. E., Pauneto, C. D. M. A., Barnett, A., & Coleman, L. G. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.886634 · Cited by 35
The Imbalance of Vascular Molecules in Alzheimer's Disease
Bell, R. D. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121060 · Cited by 34
“may actually reduce the risk of developing AD [60].”
Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes
Guo, S., Wang, S., Kim, W. J., Lee, S.-R., Frosch, M. P., Bacskai, B. J., Greenberg, S. M., & Lo, E. H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.06.041 · Cited by 35
McMichael, G., Gibson, C. S., Goldwater, P. N., Haan, E., Priest, K., Dekker, G., & MacLennan, A. H. (2008) · Human Genetics · doi:10.1007/s00439-008-0564-y · Cited by 35
“Conversely, 2, appears to have a protective role in adults (Corder et al. 1994).”
BackgroundInfluentialAssociation mapping for drought tolerance in barley at the reproductive stage
Abou‐Elwafa, S. F. (2016) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2015.12.002 · Cited by 33
Genetic predictors of common disease: Apolipoprotein E genotype as a paradigm
Jarvik, G. P. (1997) · Annals of Epidemiology · doi:10.1016/s1047-2797(97)00028-8 · Cited by 34
Diagnosis of Alzheimer's Disease
Reisberg, ., Burns, A. S., Brodaty, H., Eastwood, R., Rossor, M. N., Sartorius, N., & Winblad, B. G. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004675 · Cited by 38
“Persons with the APOE-~2 allele are at lower risk for the development of AD (Corder et al., 1994).”
BackgroundAnalysis of a Novel Mechanism of Neuronal Toxicity Produced by an Apolipoprotein E‐Derived Peptide
Moulder, K. L., Narita, M., Chang, L. K., Bu, G., & Johnson, E. M. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721069.x · Cited by 34
Kloske, C. M., Belloy, M. E., Blue, E. E., Bowman, G. R., Carrillo, M. C., Chen, X., Chiba‐Falek, O., Davis, A. A., Paolo, G. D., Garretti, F., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13877 · Cited by 33
Panza, F., Solfrizzi, V., Torres, F., Mastroianni, F., Colacicco, A. M., Basile, A. M., Capurso, C., D'Introno, A., Del Parigi, A., & Capurso, A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01447-6 · Cited by 33
APOE ε4 is associated with earlier symptom onset in LOAD but later symptom onset in EOAD
Polsinelli, A. J., Lane, K. A., Manchella, M. K., Logan, P. E., Gao, S., & Apostolova, L. G. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12955 · Cited by 38
Additional mechanisms conferring genetic susceptibility to Alzheimer’s disease
Calero, M., Gómez‐Ramos, A., Calero, O., Soriano, E., Ávila, J., & Medina, M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00138 · Cited by 45
“Mutations in those three genes account for one third to one half of all autosomal dominant cases, which in turn represent less than 1% of total AD cases (reviewed in Guerreiro et al., 2012).”
BackgroundLongitudinal change in working memory as a function of APOE genotype in midlife and old age
Greenwood, P. M., Espeseth, T., Lin, M., Reinvang, I., & Parasuraman, R. (2014) · Scandinavian Journal of Psychology · doi:10.1111/sjop.12123 · Cited by 39
“Because the ε2 allele is associated with reduced risk of AD (Corder et al., 1994), these effects on white matter do not appear to be related to development of AD.”
BackgroundAPOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease
Brookhouser, N., Raman, S., Frisch, C., Srinivasan, G., & Brafman, D. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01076-3 · Cited by 33
“respect to AD, compared with individuals homozygous for the APOE3 allele (referred to as the “risk neutral” allele), heterozygosity for the ε4 allele increases AD risk by 3 fold, and homozygosity for the ε4 allele increases risk over 10 fold [4, 5].”
BackgroundiPSCs: A Preclinical Drug Research Tool for Neurological Disorders
Bonaventura, G., Iemmolo, R., Attaguile, G. A., Cognata, V. L., Pistone, B. S., Raudino, G., D’Agata, V., Cantarella, G., Barcellona, M. L., & Cavallaro, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094596 · Cited by 36
“In particular, ε4 allele was associated to an increased risk up to three-fold in the heterozygous carriers and up to 15-fold in the homozygous [22], while ε2 allele was reported as a protective factor, reducing the AD risk [23].”
BackgroundAPOE Genotype and Functional Outcome Following Aneurysmal Subarachnoid Hemorrhage
Gallek, M. J., Conley, Y. P., Sherwood, P. R., Horowitz, M. B., Kassam, A. B., & Alexander, S. A. (2008) · Biological Research For Nursing · doi:10.1177/1099800408323221 · Cited by 31
“The APOE4 genotype has been associated with increased incidence of Alzheimer’s disease (Corder et al., 1993, 1994; Okuizumi et al., 1994; Roses, 1994; Roses et al., 1994; van Duijn et al., 1994), and poorer outcome after cerebral hemorrhage (Alberts et al., 1995), subarachnoid hemorrhage (SAH;…”
BackgroundLaDu, M. J., Munson, G. W., Jungbauer, L., Getz, G. S., Reardon, C. A., Tai, L. M., & Yu, C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.11.005 · Cited by 30
“ApoE modulates risk for AD, with ε2/2 decreasing risk 4-fold and ε4/4 increasing risk 12 fold [1-3].”
BackgroundFunctional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease
Cheng, D., Huang, R., Lanham, I. S., Cathcart, H. M., Howard, M., Corder, E. H., & Poduslo, S. E. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024968 · Cited by 33
Self-citationHarringtonaa, C. R., Anderson, J. R., & Chan, K. K. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(94)11108-u · Cited by 34
Traykov, L., Rigaud, A., Caputo, L., Couderc, R., Coste, J., Michot, J., de Rotrou, J., Amouyel, P., Forette, F., & Boller, F. (1999) · European Journal of Neurology · doi:10.1046/j.1468-1331.1999.640415.x · Cited by 33
APOE genotyping in differential diagnosis of Alzheimer's disease
Slooter, A. J. C., Breteler, M. M. B., Ott, A., Broeckhoven, C. V., & van Duijn, C. M. (1996) · The Lancet · doi:10.1016/s0140-6736(05)64501-1 · Cited by 35
APOE and metabolic dysfunction in Alzheimer's disease
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.02.002 · Cited by 31
Human APOE genotype affects intraneuronal A 1-42 accumulation in a lentiviral gene transfer model
Zhao, W., Dumanis, S. B., Tamboli, I. Y., Rodriguez, G. A., Jo LaDu, M., Moussa, C. E. H., & William Rebeck, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt525 · Cited by 32
Preman, P., Moechars, D., Fertan, E., Wolfs, L., Serneels, L., Shah, D., Lamote, J., Poovathingal, S., Snellinx, A., Mancuso, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00162-7 · Cited by 32
“…identi fi ed 30 years ago as the major genetic risk factor for Alzheimer ’ s Disease (AD) at the population level (Bennett et al, 2009; Corder et al, 1993; Strittmatter et al, 1993) while the APOE2 variant was the fi rst identi fi ed protective allele against AD (Corder et al, 1994; Nagy et al, 1995).”
Tensaouti, Y., Yu, T.-S., & Kernie, S. G. (2020) · PLOS ONE · doi:10.1371/journal.pone.0229240 · Cited by 32
“ApoE2 is the rarest allele in the population and is thought to have neuro-protective effects [28], while ApoE4 occurs in approximately twenty percent of the population and is the greatest known genetic risk factor associated with the development of late-onset Alzheimer’s disease [29].”
Hu, Y., Meuret, C., Go, S., Yassine, H. N., & Nedelkov, D. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200203 · Cited by 32
Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review
Vogrinc, D., Goričar, K., & Dolžan, V. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.646901 · Cited by 36
“On the other hand, a protective effect of APOE2 was shown (Corder et al., 1994).”
BackgroundJohnson, J. K., McCleary, R., Oshita, M. H., & Cotman, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00363-1 · Cited by 33
Object naming and semantic fluency among individuals with genetic risk for Alzheimer's disease
Miller, K. J., Rogers, S. A., Siddarth, P., & Small, G. W. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1262 · Cited by 35
“Corder et al. (1994) estimated that each additional copy increases one’s risk by a factor of four.”
BackgroundSelf-citationTranscriptional Regulation of the Mouse Presenilin-1 Gene
Mitsuda, N., Roses, A. D., & Vitek, M. P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23489 · Cited by 36
Self-citationThe ApoE Locus and COVID-19: Are We Going Where We Have Been?
Finch, C. E., & Kulminski, A. M. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa200 · Cited by 32
Haraldsen, I., Hatlestad‐Hall, C., Marra, C., Renvall, H., Maestú, F., Acosta-Hernández, J., Alfonsín, S., Andersson, V., Anand, A., Ayllón, V., et al. (2024) · Frontiers in Neurorobotics · doi:10.3389/fnbot.2023.1289406 · Cited by 37
Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry
Wildsmith, K. R., Han, B., & Bateman, R. J. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.07.049 · Cited by 31
“ApoE2 decreases the risk for developing AD [1] while ApoE4 increases the risk of developing AD.”
BackgroundChiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran‐Sacrey, D., Raptentsetsang, S. T., Thompson, P. M., Reiman, E. M., Jack, C. R., Fox, N. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.12.010 · Cited by 31
“We excluded 33 subjects who carried a minimum of one APOE 3 2 allele to avoid confounding the analysis because APOE 3 2 is believed to be protective against development of AD and associated with slower rates of hippocampal atrophy [31,32].”
Kulminski, A. M., Raghavachari, N., Arbeev, K. G., Culminskaya, I. V., Arbeeva, L. S., Wu, D., Ukraintseva, S. V., Christensen, K., & Yashin, A. I. (2016) · Biogerontology · doi:10.1007/s10522-016-9659-3 · Cited by 35
“2004),Alzheimer disease (AD) (Corder et al. 1994), and mortality (Mahley and Rall 2000).”
BackgroundCDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
Ahmad, S., Milan, M. D. C., Hansson, O., Demirkan, A., Agustin, R., Sáez, M. E., Giagtzoglou, N., Cabrera-Socorro, A., Bakker, M. H. M., Ramirez, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65038-5 · Cited by 31
“The levels of CSF AD-related biomarkers (Aβ42, total and phosphorylated tau [t-Tau and p-Tau181]) were analyzed at Amsterdam UMC as part of the routine diagnostic procedure using commercially available kits (Innotest Aβ(1-42), total Tau, phospho-Tau(181 P); Fujirebio, Ghent, Belgium)10,24.”
MethodGenotyping of Apolipoprotein E: Comparative Evaluation of Different Protocols
Ingelsson, M., Shin, Y., Irizarry, M. C., Hyman, B. T., Lilius, L., Forsell, C., & Graff, C. (2003) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0914s38 · Cited by 31
Sohrabi, H. R., Bates, K. A., Rodrigues, M. A., Taddei, K., Martins, G., Laws, S. M., Lautenschlager, N. T., Dhaliwal, S. S., Foster, J. K., & Martins, R. N. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1018 · Cited by 36
“The APOE-ε 3 allele is the most common allele [7], while the ε 2 allele appears to have a protective role against late onset AD [8].”
Ercoli, L., Siddarth, P., Huang, S.-C., Miller, K., Bookheimer, S. Y., Wright, B. C., Phelps, M. E., & Small, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.4.442 · Cited by 31
“Possession of APOE4 confers increased risk for AD in a dose-related fashion,(24) while possession of APOE2 confers protection.(25) Several investigations have identified a relationship between APOE4 genetic risk and cognitive complaints with respect to family history of AD,(26) depression,(27,28) and cognition.”
BackgroundSelf-citationAssociation of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease
Belin, A. C., Ran, C., Anvret, A., Paddock, S., Westerlund, M., Håkansson, A. S., Nissbrandt, H., Söderkvist, P., Dizdar, N., Ahmadi, A., et al. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.06.007 · Cited by 31
Teng, E., Chow, N., Hwang, K. S., Thompson, P. M., Gylys, K. H., Cole, G. M., Jack Jr., C. R., Shaw, L. M., Trojanowski, J. Q., Soares, H. D., et al. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000368982 · Cited by 31
“The risk of developing AD is highest in carriers of an ε 4 allele [2] and lowest in carriers of an ε 2 allele [3].”
Gerdes, L. U., Vestergaard, P., Hermann, A. P., & Mosekilde, L. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1906 · Cited by 32
Monastiriotis, C., Παπάνας, Ν., Trypsianis, G. A., Karanikola, K., Veletza, S. V., & Maltezos, E. S. (2012) · Angiology · doi:10.1177/0003319712453645 · Cited by 33
HYMAN, B. T., GOMEZ‐ISLA, T., WEST, H., BRIGGS, M., CHUNG, H., GROWDON, J. H., & REBECK, G. W. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34414.x · Cited by 31
The molecular genetics of Alzheimer's disease
MULLAN, M. J., & Crawford, F. (1994) · Molecular Neurobiology · doi:10.1007/bf02816100 · Cited by 32
Jiang, S., & Bhaskar, K. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161123 · Cited by 30
“APOE genotype is the strongest genetic risk factor for late-onset AD, with two copies of the E4 allele leading to an increased risk by 12-fold [43], with the E2 allele being associated with 2-fold decreased risk for AD [44], and the E3 allele being the most common form and leading to intermediate risk of AD [45].”
Genetic Modifiers in Neurodegeneration
Jain, N., & Chen-Plotkin, A. S. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0133-1 · Cited by 30
Aziz, T. A., Nadeem, A. A., Sarwar, A., Perveen, I., Hussain, N., Khan, A. A., Daudzai, Z., Cui, H., & Lin, L. (2023) · Biomedicines · doi:10.3390/biomedicines11020354 · Cited by 33
“For this purpose, supplements can also be used [59].”
Langella, S., Barksdale, N. G., Vasquez, D., Aguillon, D., Chen, Y., Su, Y., Acosta-Baena, N., Acosta-Uribe, J., Baena, A. Y., Garcia-Ospina, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40775-z · Cited by 30
“The APOE e2 allele has also been associated with delayed onset and protection against cognitive decline in older adults 20,23,24 .”
Apolipoprotein E and the Risk of Breast Cancer in African-American and Non-Hispanic White Women
Moore, R. J., Chamberlain, R. M., & Khuri, F. R. (2004) · Oncology · doi:10.1159/000077433 · Cited by 33
Matsuo, M., Campenot, R. B., Vance, D. E., Ueda, K., & Vance, J. E. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.10.004 · Cited by 34
Hippocampal and entorhinal cortex volume decline in cognitively intact elderly
Thomann, P. A., Wüstenberg, T., Nolte, H. M., Menzel, P. B., Wolf, R. C., Essig, M., & Schröder, J. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2012.06.002 · Cited by 34
“In contrast to e4, the ApoE allele e2 is considered protective against the development of late onset AD (Corder et al., 1994).”
BackgroundGenetic Stratification to Identify Risk Groups for Alzheimer’s Disease
Marioni, R. E., Campbell, A., Hagenaars, S. P., Nagy, R., Amador, C., Hayward, C., Porteous, D. J., Visscher, P. M., & Deary, I. J. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161070 · Cited by 30
“Keywords: Alzheimer’s disease, apolipoprotein E, cognitive function, genetics, polygenic traits”
BackgroundHorn, M. M., Kennedy, K. M., & Rodrigue, K. M. (2018) · Psychology and Aging · doi:10.1037/pag0000217 · Cited by 32
“…are very rare, and heterozygotes relatively rare in the population, making these subgroups smaller, and potentially biased to be cognitively healthy enough for inclusion in a healthy aging study, as APOE ε4 is associated with an earlier onset of AD (Corder et al., 1994; Farrer et al., 1997).”
Mechanisms that minimize retinal impact of apolipoprotein E absence
Saadane, A., Petrov, A. M., Mast, N., El‐Darzi, N., Dao, T. V., Alnemri, A. G., Song, Y., Dunaief, J. L., & Pikuleva, I. A. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m090043 · Cited by 32
Opposing Roles of apolipoprotein E in aging and neurodegeneration
Hudry, E., Klickstein, J., Cannavo, C., Jackson, R., Muzikansky, A., Gandhi, S., Urick, D., Sargent, T., Wrobleski, L., Roe, A. D., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900325 · Cited by 30
“APOE, the major apolipoprotein of the brain and most important genetic contributor to the sporadic form of AD (Wisniewski & Frangione, 1992; Corder et al, 1993, 1994; West et al, 1994; Hyman et al, 1996; Lippa et al, 1997), is a well-established partner of amyloid β peptides and has been shown to…”
BackgroundVidal, J., Verchere, C. B., Andrikopoulos, S., Wang, F., Hull, R. L., Cnop, M., Olin, K., LeBoeuf, R. C., O’Brien, K. D., Chait, A., et al. (2003) · Diabetologia · doi:10.1007/s00125-002-0984-5 · Cited by 34
“Moreover, these experimental data are supported by the strong association between the apoE4 allele and an increased age-adjusted risk of developing Alzheimer’s disease when compared to subjects who inherit the more common apoE alleles [27].”
BackgroundRoses, A. D. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90197-x · Cited by 34
Self-citationThe apolipoprotein E gene in Binswanger's disease and vascular dementia
Higuchi, S., Arai, H., Nakagawa, T., Muramatsu, T., Sasaki, H., & Trojanowski, J. Q. (1996) · Clinical Genetics · doi:10.1111/j.1399-0004.1996.tb02712.x · Cited by 30
Down syndrome: Progress in research
Roizen, N. (2001) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/1098-2779(200102)7:1<38::aid-mrdd1006>3.0.co;2-c · Cited by 39
Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology
Glass, D. J., & Arnold, S. E. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2408 · Cited by 29
“[17] Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE,”
BackgroundAge stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease
Liu, L., & Caselli, R. J. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.006 · Cited by 29
Faraone, S. V., Biederman, J., Mennin, D., & Russell, R. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980207)81:1<108::aid-ajmg18>3.0.co;2-n · Cited by 67
Self-citationState of the art paper APOE gene polymorphisms and diabetic peripheral neuropathy
Monastiriotis, C., Παπάνας, Ν., Veletza, S. V., & Maltezos, E. S. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.30279 · Cited by 29
“Secondly, human studies have provided evidence that the APOE4 allele confers increased risk of developing early Alzheimer’s disease [22], while the APOE2 allele lowers this risk [23].”
BackgroundGardner, O. K., Wang, L., Booven, D. V., Whitehead, P. L., Hamilton‐Nelson, K. L., Adams, L. D., Starks, T. D., Hofmann, N. K., Vance, J. M., Cuccaro, M. L., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz110 · Cited by 43
Self-citationThe Impact of Complement Genes on the Risk of Late-Onset Alzheimer’s Disease
Carpanini, S. M., Harwood, J. C., Baker, E. A., Torvell, M., Sims, R., Williams, J. H., & Morgan, B. P. (2021) · Genes · doi:10.3390/genes12030443 · Cited by 30
“…accounting for the large majority of AD cases, the strongest genetic risk factor is the presence of the ε 4 allele of the gene encoding Apolipoprotein E (ApoE); ε 4 confers increased risk, while the most common allele, ε 3, is considered neutral for AD, and ε 2 has a minor protective effect [8–11].”
BackgroundRelationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease
Whitwell, J. L., Tosakulwong, N., Weigand, S. D., Graff‐Radford, J., Ertekin‐Taner, N., Machulda, M. M., Duffy, J. R., Schwarz, C. G., Senjem, M. L., Jack, C. R., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.012 · Cited by 29
Primary age‐related tauopathy in a Finnish population‐based study of the oldest old (Vantaa 85+)
Savola, S. E., Kaivola, K., Raunio, A., Kero, M., Mäkelä, M., Pärn, K., Palta, P., Tanskanen, M., Tuimala, J., Polvikoski, T. M., et al. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12788 · Cited by 30
“Interestingly, PART is not associated with the APOE ε4 allele but rather with the APOE ε2 allele [19], which is noteworthy because the APOE ε4 allele is commonly known as the strongest genetic risk factor for sporadic late-onset AD [20], whereas APOE ε2 might have more of a protective role [21].”
BackgroundSeaks, C. E., Weekman, E. M., Sudduth, T. L., Xie, K., Wasek, B., Fardo, D. W., Johnson, L. A., Bottiglieri, T., & Wilcock, D. M. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211069006 · Cited by 30
Functional variants identify sex-specific genes and pathways in Alzheimer’s Disease
Bourquard, T., Lee, K. D., Al‐Ramahi, I., Pham, M., Shapiro, D., Lagisetty, Y., Soleimani, S., Mota, S., Wilhelm, K. O., Samieinasab, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38374-z · Cited by 36
“Genome-wide association studies (GWAS) have found more than 30 LOAD-associated loci 15 – 18 accounting for ~0.33 19 of the heritability (mostly explained by APOE ε 4 ) 20,21 .”
InfluentialAndrews, S. J., Das, D., Anstey, K. J., & Easteal, S. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-140630 · Cited by 35
“In contrast, possession of the APOE∗ 2 allele, which has been associated with reduced risk of Alzheimer’s disease [7], may protect against cognitive decline [8, 9].”
BackgroundCommon apolipoprotein E polymorphisms and risk of clinical malaria in the Gambia
Aucan, C., Walley, A. J., & Hill, A. V. S. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.011981 · Cited by 29
Effects of the APOE 2 Allele on Mortality and Cognitive Function in the Oldest Old
Lindahl-Jacobsen, R., Tan, Q., Mengel-From, J., Christensen, K., Nebel, A., & Christiansen, L. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls192 · Cited by 29
“2005 38 (21) 26 (15) 113 (63) 2 (1) Fluency task (mean, standard deviation) (12.”
ApoE4-specific Misfolded Intermediate Identified by Molecular Dynamics Simulations
Williams II, B., Convertino, M., Das, J., & Dokholyan, N. V. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004359 · Cited by 29
Stich, B., Melchinger, A. E., Piepho, H., Hamrit, S., Schipprack, W., Maurer, H. P., & Reif, J. C. (2007) · Theoretical and Applied Genetics · doi:10.1007/s00122-007-0586-1 · Cited by 31
“1989) and Alzheimer’s disease ( Corder et al. 1994 ).”
BackgroundDafnis, I., Raftopoulou, C., Mountaki, C., Megalou, E., Zannis, V. I., & Chroni, A. (2018) · Biochemical Journal · doi:10.1042/bcj20180068 · Cited by 29
Reiman, E. M., Caselli, R. J., Alexander, G. E., & Chen, K. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(01)00006-8 · Cited by 28
Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease
Ibarreta, D., Gómez‐Isla, T., Portera‐Sánchez, A., Parrilla, R., & Ayuso, M. S. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00238-3 · Cited by 34
Kalman, J. L., Juhász, A., Császár, A., Kanka, A., Maglóczky, E., Bencsik, K., Janka, Z., & Raskó, I. (1997) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1997.tb00069.x · Cited by 30
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
“Mouse J20 line of hAPPFAD and overexpressing APOE 272-299 ApoE4 (1-271)1 (N-terminal) Decreases Aβ clearance and increases Aβ deposition In vivo/ In vitro Full-length ApoE3 and ApoE4 expressing mice were able to stimulate Aβ clearance Bien-Ly et al.”
BackgroundMolecular recognition of the interaction between ApoE and the TREM2 protein
Mai, Z., Wei, W., Yu, H., Chen, Y., Wang, Y., & Ding, Y. (2022) · Translational Neuroscience · doi:10.1515/tnsci-2022-0218 · Cited by 33
“Conversely, ApoE2 shows a protective effect, with decreased risk and later age at onset of AD [7].”
BackgroundBonner-Jackson, A., Okonkwo, O., & Tremont, G. (2012) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3182203c32 · Cited by 28
“We found significant main effects of Genotype [F(1,590) = 7.”
InfluentialAssessment of APOE in atypical parkinsonism syndromes
Sabir, M. S., Blauwendraat, C., Ahmed, S., Serrano, G. E., Beach, T. G., Perkins, M., Rice, A. C., Masliah, E., Morris, C. M., Pihlstrom, L., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.016 · Cited by 28
APOE region molecular signatures of Alzheimer's disease across races/ethnicities
Kulminski, A. M., Shu, L., Loika, Y., Nazarian, A., Arbeev, K. G., Ukraintseva, S. V., Yashin, A. I., & Culminskaya, I. V. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.11.007 · Cited by 28
Apolipoprotein E Activates Akt Pathway in Neuro-2a in an Isoform-Specific Manner
Laffont-Proust, I., Takahashi, M., Shibukawa, Y., Honke, K., Shuvaev, V. V., Siest, G., Visvikis‐Siest, S., & Taniguchi, N. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6586 · Cited by 31
Tsuang, D. W., & Bird, T. D. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00003-2 · Cited by 29
“In addition, several studies suggest a reduced frequency of the APOE e2 allele in AD patients [37,38].”
BackgroundApolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins
Strickland, M. R., Rau, M. J., Summers, B., Basore, K., Wulf, J., Jiang, H., Chen, Y., Ulrich, J. D., Randolph, G. J., Zhang, R., et al. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.018 · Cited by 28
Pettigrew, C. A., Nazarovs, J., Soldan, A., Singh, V., Wang, J., Hohman, T. J., Dumitrescu, L. C., Libby, J. B., Kunkle, B. W., Gross, A. L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01206-9 · Cited by 33
“The ε4 allele of the apolipoprotein-E gene (APOE-ε4) is a well-known risk factor for late onset AD dementia [7, 8], whereas the APOE ε2 allele (APOE-ε2) is associated with a reduced risk of AD dementia [9, 10].”
BackgroundThe influence of APOEε4 on the pTau interactome in sporadic Alzheimer’s disease
Thierry, M., Ponce, J., Martá-Ariza, M., Askenazi, M., Faustin, A., Leitner, D., Pires, G., Kanshin, E., Drummond, E., Ueberheide, B. M., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02744-8 · Cited by 30
“In contrast, the rare APOE ε2 allele confers a protection against the development of AD (Odds Ratio APOE ε2/ε2 = 0.7; www. alzge ne. org; [18]).”
BackgroundInfluentialKim, H., Kim, D.-K., Choi, I.-J., Kang, K. H., Yi, S., Park, J., & Park, Y. (2001) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2001.00797.x · Cited by 32
Amyloid-β: The seeds of darkness
Fodero‐Tavoletti, M. T., Villemagne, V. L., Rowe, C. C., Masters, C. L., Barnham, K. J., & Cappai, R. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.05.001 · Cited by 34
Current Strategies and Novel Drug Approaches for Alzheimer Disease
Ghai, R., Nagarajan, K., Arora, M., Grover, P., Ali, N., & Kapoor, G. T. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200717091513 · Cited by 31
Influence of APOE genotype in primary age-related tauopathy
Robinson, A., Davidson, Y. S., Roncaroli, F., Minshull, J., Tinkler, P., Horan, M. A., Payton, A., Pendleton, N., & Mann, D. M. A. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01095-1 · Cited by 27
Marca-Ysabel, M. V., Rajabli, F., Cornejo‐Olivas, M., Whitehead, P. G., Hofmann, N. K., Illanes‐Manrique, M., Véliz-Otani, D., Milla‐Neyra, K., Castro‐Suárez, S., Meza-Vega, M., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.10.003 · Cited by 37
Self-citationBeyond the amyloid cascade: An update of Alzheimer's disease pathophysiology
Gouilly, D., Rafiq, M., Nogueira, L., Salabert, A., Payoux, P., Péran, P., & Pariente, J. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2022.12.006 · Cited by 35
Garai, K., Baban, B., & Frieden, C. (2011) · Biochemistry · doi:10.1021/bi2006702 · Cited by 27
Influence of apolipoprotein E polymorphism on plasma vitamin A and vitamin E levels
Gómez‐Coronado, D., Bueno, A. E., Álvarez, J. J., Ortega, H., Olmos, J. M., Castro, M., Sastre, A., Herrera, E., & Lasunción, M. A. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00983.x · Cited by 28
ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy
Montañola, A., de Retana, S. F., López‐Rueda, A., Merino-Zamorano, C., Peñalba, A., Fernández‐Álvarez, P., Rodríguez‐Luna, D., Malagelada, A., Pujadas, F., Montaner, J., et al. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8381-7 · Cited by 33
“On the other hand, APOE2 allele has been described to be associated with a lower risk of AD (Corder et al. 1994).”
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of California, Los Angeles (US)
- Venue
- Nature Genetics
- Published
- 1994-06
- Volume
- 7
- Issue
- 2
- Pages
- 180-184
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2090271811
- Cited by
- 1,920
- References
- 41
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 78 · 2023: 59 · 2022: 66 · 2021: 76 · 2020: 76 · 2019: 58 · 2018: 62 · 2017: 58 · 2016: 75 · 2015: 55 · 2014: 63 · 2013: 68 · 2012: 66
- FWCI
- 54.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (NIA AG05128, U24AG021886)
- National Institute of Neurological Disorders and Stroke (P01NS026630, NINDS NS26630, NINDS NS531153)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, familial Alzheimer's disease, gene dosage, protective effect, sporadic Alzheimer's disease, genetic risk factors, APOE genotype
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Risk Factors, Odds Ratio, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.